Product News

Share this article:

Johnson & Johnson subsidiary Centocor Ortho Biotech received FDA approval for Simponi, an injectable treatment for arthritis caused by immune-system disorders. According to an AP report, the drug is a potential blockbuster, and a follow-up to Remicade, a multibillion-dollar seller. Simponi will be marketing in the US by J&J, and in Europe by Schering-Plough.

 

FDA authorized a relaxed indication and distribution of Roche's and GlaxoSmithKline's antiviral drugs – Tamiflu and Relenza, respectively – in order to combat swine flu. Public health officials and volunteers will be allowed to distribute the meds, and both drugs will be available off-label, based on FDA's “Emergency Use Authorization” provision.

 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.